PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $PACB in the last 7 days.
Pacific Biosciences (PACB) stock rose 13.28% on optimism over its Vega sequencing platform upgrade. The company announced a 50% increase in data output and a 40% cost reduction per run. New CEO Mark Van Oene succeeds Christian Henry, who remains as an advisor. PACB reported $39M revenue, $44.7M net loss, and $236.9M in cash. Traders are watching for momentum driven by the upgrade and leadership change.
MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.
Merck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.
Recent PACB coverage spans market movers, earnings and technology.
In the last 30 days, PACB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($30K). The most active reporter was Van Oene Mark, See Remarks, with 1 filing.
The upgrade promises higher output and lower cost per gigabase, potentially boosting lab adoption and driving short‑term buying pressure.
Limited direct exposure but may benefit from broader sequencing adoption.
Increased need for long‑read sequencing could boost PacBio’s revenue outlook.
The miss on both revenue and adjusted EPS increases near-term downside risk to expectations and supports a cautious stance until next-quarter execution improves.
The filing provides fresh quarterly datapoints and a new full-year revenue range, which can reset near-term expectations for instrument pull-through and consumables growth.
alphai scores every news story that mentions PACB with an AI model for sentiment and relevance, and aggregates insider trades from PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Pacific Biosciences (PACB) stock rose 13.28% on optimism over its Vega sequencing platform upgrade. The company announced a 50% increase in data output and a 40% cost reduction per run. New CEO Mark Van Oene succeeds Christian Henry, who remains as an advisor. PACB reported $39M revenue, $44.7M net loss, and $236.9M in cash. Traders are watching for momentum driven by the upgrade and leadership change.
3 min readMRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.
3 min readMerck (MRK) and Moderna (MRNA) announced positive Phase III results for their cancer vaccine, intismeran, showing improved outcomes when combined with Keytruda. Shares of both companies surged, with Moderna gaining 130.5% over three days. Sequencing companies like Illumina (ILMN) and PacBio (PACB) also saw gains due to the personalized nature of the therapy. Analysts upgraded Moderna's stock, citing broadened sales potential, while others remained cautious about long-term expectations.
3 min readPacific Biosciences of California (NASDAQ:PACB) reported Q2 CY2026 revenue of $39.01 million, down 1.9% year on year and below analyst expectations. Non-GAAP adjusted EPS was -$0.14, missing consensus. Analysts expect revenue to rise 14.2% over the next 12 months and full-year EPS to improve from -$0.50 to -$0.48. Shares fell 1.1% to $1.28 after results.
5 min readPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PacBio Announces Second Quarter 2026 Financial Results MENLO PARK, Calif., August 5, 2026 (GLOBE NEWSWIRE) – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights • Total revenue of $39.0 million was d
6 min readPacBio (NASDAQ: PACB) said it will add SPRQ-Nx chemistry and a software update for its Vega sequencing system. The chemistry uses Revio core chemistry to raise HiFi output from 60 Gb to 90 Gb per run and cut the U.S. list price from $1,100 to $995. The update adds 2- and 4-hour runs, new methylation callers, and 21 CFR Part 11 compliance controls. Shipping and download are planned by month-end.
4 min readPacific Biosciences of California (NASDAQ: PACB) will report earnings Wednesday afternoon. Last quarter it reported revenue of $37.18 million, flat year over year, missing analysts’ revenue expectations, while EPS beat. This quarter, analysts expect revenue to be flat. The article cites an average analyst price target of $2.46 versus $1.43.
3 min readPACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. pacb-20260708 0001299130 false 0001299130 2026-07-08 2026-07-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) Ju
2 min readThe article compares Q1 results across life-sciences tools stocks. West Pharmaceutical Services posted the biggest analyst estimate beat; its shares were up 18% to $323.85. Azenta reported $144.8M revenue (+1% YoY), missing expectations by 2.5%, and shares fell 5.8% to $23.19. Bruker revenue was $823.4M (+2.7%), beating by 3.4%, shares up 56% to $59.30. Illumina revenue was $1.09B (+4.8%), beating by 1.8%, shares up 29.1% to $163.68.
6 min readPacific Biosciences of California, Inc. (PACB) reported Q1 2026 revenue of $37.2 million, flat year-over-year, with higher consumable sales offsetting declines in instrument and service revenue. The company significantly narrowed its net loss to $8.3 million, down from $426.1 million in Q1 2025, largely due to a $45.8 million gain on an asset sale to Illumina and reduced operating expenses. PACB expects sequential revenue growth in Q2 2026 and further improvements in the second half of the year driven by clinical adoption, SPRQ-Nx consumable growth, and its Basecamp Research program.
3 min read
